Seminars in hematology最新文献

英文中文

A Call to Arms: Overcoming challenges in Myelodysplastic Syndromes therapy advances 武器的召唤：克服骨髓增生异常综合症治疗进展中的挑战。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.11.005

Kathy L. McGraw , Peter D. Aplan , Steven Z. Pavletic

引用次数: 0

Cellular and immunotherapies for myelodysplastic syndromes 骨髓增生异常综合征的细胞和免疫疗法。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.09.006

Ryan J. Stubbins , Hannah Cherniawsky , Aly Karsan

In this review article, we outline the current landscape of immune and cell therapy-based approaches for patients with myelodysplastic syndromes (MDS). Given the well characterized graft-versus-leukemia (GVL) effect observed with allogeneic hematopoietic cell transplantation, and the known immune escape mechanisms observed in MDS cells, significant interest exists in developing immune-based approaches to treat MDS. These attempts have included antibody-based drugs that block immune escape molecules, such as inhibitors of the PD-1/PD-L1 and TIM-3/galectin-9 axes that mediate interactions between MDS cells and T-lymphocytes, as well as antibodies that block the CD47/SIRPα interaction, which mediates macrophage phagocytosis. Unfortunately, these approaches have been largely unsuccessful. There is significant potential for T-cell engaging therapies and chimeric antigen receptor T (CAR-T) cells, but there are also several limitations to these approaches that are unique to MDS. However, many of these limitations may be overcome by the next generation of cellular therapies, including those with engineered T-cell receptors or natural killer (NK)-cell based platforms. Regardless of the approach, all these immune cells are subject to the complex bone marrow microenvironment in MDS, which harbours a variable and heterogeneous mix of pro-inflammatory cytokines and immunosuppressive elements. Understanding this interaction will be paramount to ensuring the success of immune and cellular therapies in MDS.

在这篇综述文章中，我们概述了目前治疗骨髓增生异常综合征（MDS）患者的基于免疫和细胞疗法的方法。鉴于同种异体造血细胞移植中观察到的移植物抗白血病（GVL）效应以及在 MDS 细胞中观察到的已知免疫逃逸机制，人们对开发基于免疫的方法来治疗 MDS 产生了浓厚的兴趣。这些尝试包括阻断免疫逃逸分子的抗体药物，如介导 MDS 细胞与 T 淋巴细胞相互作用的 PD-1/PD-L1 和 TIM-3/galectin-9 轴抑制剂，以及阻断介导巨噬细胞吞噬作用的 CD47/SIRPα 相互作用的抗体。遗憾的是，这些方法基本上都不成功。T细胞参与疗法和嵌合抗原受体T（CAR-T）细胞具有巨大的潜力，但这些方法也存在一些MDS特有的局限性。不过，下一代细胞疗法（包括具有工程T细胞受体或基于自然杀伤（NK）细胞平台的疗法）可能会克服其中的许多局限性。无论采用哪种方法，所有这些免疫细胞都会受到 MDS 复杂骨髓微环境的影响，因为骨髓微环境中存在着多种多样的促炎细胞因子和免疫抑制因子。了解这种相互作用对于确保 MDS 免疫疗法和细胞疗法的成功至关重要。

{"title":"Cellular and immunotherapies for myelodysplastic syndromes","authors":"Ryan J. Stubbins , Hannah Cherniawsky , Aly Karsan","doi":"10.1053/j.seminhematol.2024.09.006","DOIUrl":"10.1053/j.seminhematol.2024.09.006","url":null,"abstract":"<div><div>In this review article, we outline the current landscape of immune and cell therapy-based approaches for patients with myelodysplastic syndromes (MDS). Given the well characterized graft-versus-leukemia (GVL) effect observed with allogeneic hematopoietic cell transplantation, and the known immune escape mechanisms observed in MDS cells, significant interest exists in developing immune-based approaches to treat MDS. These attempts have included antibody-based drugs that block immune escape molecules, such as inhibitors of the PD-1/PD-L1 and TIM-3/galectin-9 axes that mediate interactions between MDS cells and T-lymphocytes, as well as antibodies that block the CD47/SIRPα interaction, which mediates macrophage phagocytosis. Unfortunately, these approaches have been largely unsuccessful. There is significant potential for T-cell engaging therapies and chimeric antigen receptor T (CAR-T) cells, but there are also several limitations to these approaches that are unique to MDS. However, many of these limitations may be overcome by the next generation of cellular therapies, including those with engineered T-cell receptors or natural killer (NK)-cell based platforms. Regardless of the approach, all these immune cells are subject to the complex bone marrow microenvironment in MDS, which harbours a variable and heterogeneous mix of pro-inflammatory cytokines and immunosuppressive elements. Understanding this interaction will be paramount to ensuring the success of immune and cellular therapies in MDS.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 6","pages":"Pages 397-408"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding MDS stem cells: Advances and limitations 了解 MDS 干细胞：进展与局限。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.09.007

Sweta B. Patel , Daniel R. Moskop , Craig T. Jordan, Eric M. Pietras

In work spanning several decades, extensive studies have focused on the properties of malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However, relatively little attention has been devoted to several serious myeloid malignancies that occur prior to the onset of frank leukemia, including myelodysplastic syndrome (MDS). Like leukemia, MDS is hypothesized to arise from a pool of immature malignant stem and progenitor cells (MDS-SCs) that serve as a reservoir for disease evolution and progression¹. While multiple studies have sought to identify and characterize the biology and vulnerabilities of MDS-SCs, yet translation of scientific concepts to therapeutically impactful regimens has been limited. Here, we evaluate the currently known properties of MDS-SCs as well as the post-transcriptional mechanisms that drive MDS pathogenesis at a stem and progenitor level. We highlight limits and gaps in our characterization and understanding of MDS-SCs and address the extent to which the properties of MDS-SC are (and can be) inferred from the characterization of LSCs.

在长达数十年的工作中，大量研究都集中在驱动急性髓性白血病（AML）发病机制的恶性干细胞特性上。然而，人们对几种严重骨髓恶性肿瘤的关注相对较少，这些恶性肿瘤发生在白血病发病之前，包括骨髓增生异常综合征（MDS）。与白血病一样，骨髓增生异常综合症也被认为是由未成熟的恶性干细胞和祖细胞（MDS-SCs）引起的，这些细胞是疾病演变和发展的蓄水池1。虽然已有多项研究试图确定和描述MDS-SCs的生物学特性和脆弱性，但将科学概念转化为具有治疗效果的治疗方案的工作还很有限。在此，我们评估了目前已知的MDS-SCs特性，以及在干细胞和祖细胞水平上驱动MDS发病的转录后机制。我们强调了我们对MDS-SC特性描述和理解的局限性和差距，并探讨了从LSC特性描述中推断MDS-SC特性的程度（以及可以推断的程度）。

{"title":"Understanding MDS stem cells: Advances and limitations","authors":"Sweta B. Patel , Daniel R. Moskop , Craig T. Jordan, Eric M. Pietras","doi":"10.1053/j.seminhematol.2024.09.007","DOIUrl":"10.1053/j.seminhematol.2024.09.007","url":null,"abstract":"<div><div>In work spanning several decades, extensive studies have focused on the properties of malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However, relatively little attention has been devoted to several serious myeloid malignancies that occur prior to the onset of frank leukemia, including myelodysplastic syndrome (MDS). Like leukemia, MDS is hypothesized to arise from a pool of immature malignant stem and progenitor cells (MDS-SCs) that serve as a reservoir for disease evolution and progression<sup>1</sup>. While multiple studies have sought to identify and characterize the biology and vulnerabilities of MDS-SCs, yet translation of scientific concepts to therapeutically impactful regimens has been limited. Here, we evaluate the currently known properties of MDS-SCs as well as the post-transcriptional mechanisms that drive MDS pathogenesis at a stem and progenitor level. We highlight limits and gaps in our characterization and understanding of MDS-SCs and address the extent to which the properties of MDS-SC are (and can be) inferred from the characterization of LSCs.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 6","pages":"Pages 409-419"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications for metabolic disturbances in myelodysplastic syndromes 骨髓增生异常综合征代谢紊乱的影响。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.11.004

Kathy L. McGraw , Daniel R. Larson

The Myelodysplastic Syndromes (MDS) are heterogeneous stem cell malignancies clinically characterized by bone marrow dysplasia, peripheral blood cytopenias, and a high risk for transformation to acute myeloid leukemia. In early stages of disease, differentiation defects and maturation blocks result in deficient hematopoiesis. In higher risk disease, unrestricted proliferation of immature blast cells leads to leukemogenesis. Disease pathogenesis can be attributed to many factors including chronic inflammation that is driven in part by commonly found somatic gene mutations (SGM) fostering expansion of malignant clones while suppressing normal hematopoiesis. Cellular metabolism that both directly and indirectly regulates hematopoietic stem cell (HSC) fate, is intimately connected to the immune system, is altered by MDS somatic gene mutations and is likely is a major contributor to disease pathophysiology. Despite this likely role in pathobiology, there is an underwhelming depth of literature on the subject and the precise metabolic dysregulations in these myeloid malignancies have yet to be fully delineated. In this review, we will provide a general overview of several major metabolic processes and how each directs HSC fate, provide a summary of metabolic studies in MDS, discuss how common SGM and inflammation influence metabolic pathways to drive bone marrow failure, and end with a discussion of standards of care and how these should be carefully considered in the context of metabolic dysregulation.

骨髓增生异常综合征（MDS）是一种异质性干细胞恶性肿瘤，临床特点是骨髓发育不良、外周血细胞减少以及极易转化为急性髓性白血病。在疾病的早期阶段，分化缺陷和成熟障碍会导致造血功能缺陷。在高风险疾病中，未成熟的胚泡细胞不受限制地增殖会导致白血病的发生。疾病的发病机制可归因于多种因素，其中包括慢性炎症，而慢性炎症的部分驱动因素是常见的体细胞基因突变（SGM），这种突变在抑制正常造血的同时促进了恶性克隆的扩增。细胞代谢直接或间接调控造血干细胞（HSC）的命运，与免疫系统密切相关，MDS体细胞基因突变改变了细胞代谢，很可能是疾病病理生理学的主要因素。尽管MDS在病理生物学中可能起着重要作用，但有关这一主题的文献深度却远远不够，而且这些髓系恶性肿瘤中确切的代谢失调尚未完全阐明。在这篇综述中，我们将概述几种主要的代谢过程以及每种代谢过程如何引导造血干细胞的命运，总结 MDS 中的代谢研究，讨论常见的 SGM 和炎症如何影响代谢途径以导致骨髓衰竭，最后讨论护理标准以及如何在代谢失调的背景下仔细考虑这些标准。

{"title":"Implications for metabolic disturbances in myelodysplastic syndromes","authors":"Kathy L. McGraw , Daniel R. Larson","doi":"10.1053/j.seminhematol.2024.11.004","DOIUrl":"10.1053/j.seminhematol.2024.11.004","url":null,"abstract":"<div><div>The Myelodysplastic Syndromes (MDS) are heterogeneous stem cell malignancies clinically characterized by bone marrow dysplasia, peripheral blood cytopenias, and a high risk for transformation to acute myeloid leukemia. In early stages of disease, differentiation defects and maturation blocks result in deficient hematopoiesis. In higher risk disease, unrestricted proliferation of immature blast cells leads to leukemogenesis. Disease pathogenesis can be attributed to many factors including chronic inflammation that is driven in part by commonly found somatic gene mutations (SGM) fostering expansion of malignant clones while suppressing normal hematopoiesis. Cellular metabolism that both directly and indirectly regulates hematopoietic stem cell (HSC) fate, is intimately connected to the immune system, is altered by MDS somatic gene mutations and is likely is a major contributor to disease pathophysiology. Despite this likely role in pathobiology, there is an underwhelming depth of literature on the subject and the precise metabolic dysregulations in these myeloid malignancies have yet to be fully delineated. In this review, we will provide a general overview of several major metabolic processes and how each directs HSC fate, provide a summary of metabolic studies in MDS, discuss how common SGM and inflammation influence metabolic pathways to drive bone marrow failure, and end with a discussion of standards of care and how these should be carefully considered in the context of metabolic dysregulation.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 6","pages":"Pages 470-478"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RNA splicing as a therapeutic target in myelodysplastic syndromes 将 RNA 剪接作为骨髓增生异常综合征的治疗靶点。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.10.005

Chun-Chih Tseng, Esther A. Obeng

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological disorders and are more commonly found in people over the age of 60. MDS patients exhibit peripheral blood cytopenias and carry an increased risk of disease progression to acute myeloid leukemia (AML). Splicing factor mutations (including genes SF3B1, SRSF2, U2AF1, and ZRSR2) are early events identified in more than 50% of MDS cases. These mutations cause aberrant pre-mRNA splicing and impact MDS pathophysiology. Emerging evidence shows that splicing factor-mutant cells are more sensitive to perturbations targeting the spliceosome, aberrantly spliced genes and/or their regulated molecular pathways. This review summarizes current therapeutic strategies and ongoing efforts targeting splicing factor mutations for the treatment of MDS.

骨髓增生异常综合征（MDS）是一类异质性血液病，多见于 60 岁以上的人群。骨髓增生异常综合征患者表现为外周血细胞减少，疾病进展为急性髓性白血病（AML）的风险增加。剪接因子突变（包括基因 SF3B1、SRSF2、U2AF1 和 ZRSR2）是在 50% 以上 MDS 病例中发现的早期事件。这些突变会导致前 mRNA 剪接异常，并影响 MDS 的病理生理学。新的证据显示，剪接因子突变细胞对针对剪接体、异常剪接基因和/或其调控分子通路的干扰更敏感。本综述总结了目前针对剪接因子突变治疗 MDS 的治疗策略和正在进行的工作。

引用次数: 0

Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes 骨髓增生异常综合征患者早期试验中的患者报告结果。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.10.010

Tito Mendoza , Amanda L. King , Elizabeth Vera , Alain Mina , Kathy McGraw , Steven Pavletic , Terri S. Armstrong

Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience a wide range of symptoms due both to their underlying disease and the effects of treatment. Designing early phase trials to explore effective therapies in these patients should not only examine anti-tumor activity, but also consider the effects of treatments on how patients feel and function. Assessing symptomatic toxicities associated with new therapies in early phase trials from the patient perspective is best measured using patient-reported outcomes (PROs) and offers valuable insight and complementary information to the traditional adverse event reporting in cancer clinical trials. This review describes PROs, highlights their importance in MDS drug development, and outlines the key psychometric properties and practical considerations that make PROs essential and desirable in evaluating the impact of new therapies. We will provide a general overview of PROs and follow with application of PROs in MDS/AML including strategies to be considered in early phase trials. Finally, we describe the creation of the Office of Patient-Centered Outcomes Research at the US National Institutes of Health which has developed a standardized PROs methodology for early phase trials conducted in the Center for Cancer Research at the US National Cancer Institute.

骨髓增生异常综合征（MDS）或急性髓性白血病（AML）患者会因潜在疾病和治疗效果而出现各种症状。在设计早期试验以探索针对这些患者的有效疗法时，不仅要检查抗肿瘤活性，还要考虑治疗对患者感觉和功能的影响。从患者的角度评估早期试验中与新疗法相关的症状性毒性，最好使用患者报告的结果（PROs）来衡量，它为癌症临床试验中传统的不良事件报告提供了宝贵的见解和补充信息。本综述介绍了患者报告结果，强调了其在 MDS 药物开发中的重要性，并概述了使患者报告结果成为评估新疗法影响的关键和理想方法的关键心理测量学特性和实际考虑因素。我们将对PROs进行总体概述，然后介绍PROs在MDS/AML中的应用，包括在早期阶段试验中需要考虑的策略。最后，我们将介绍美国国立卫生研究院（US National Institutes of Health）设立的以患者为中心的结果研究办公室（Office of Patient-Centered Outcomes Research），该办公室为美国国立癌症研究所（US National Cancer Institute）癌症研究中心（Center for Cancer Research）开展的早期试验制定了标准化的PROs方法。

{"title":"Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes","authors":"Tito Mendoza , Amanda L. King , Elizabeth Vera , Alain Mina , Kathy McGraw , Steven Pavletic , Terri S. Armstrong","doi":"10.1053/j.seminhematol.2024.10.010","DOIUrl":"10.1053/j.seminhematol.2024.10.010","url":null,"abstract":"<div><div>Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience a wide range of symptoms due both to their underlying disease and the effects of treatment. Designing early phase trials to explore effective therapies in these patients should not only examine anti-tumor activity, but also consider the effects of treatments on how patients feel and function. Assessing symptomatic toxicities associated with new therapies in early phase trials from the patient perspective is best measured using patient-reported outcomes (PROs) and offers valuable insight and complementary information to the traditional adverse event reporting in cancer clinical trials. This review describes PROs, highlights their importance in MDS drug development, and outlines the key psychometric properties and practical considerations that make PROs essential and desirable in evaluating the impact of new therapies. We will provide a general overview of PROs and follow with application of PROs in MDS/AML including strategies to be considered in early phase trials. Finally, we describe the creation of the Office of Patient-Centered Outcomes Research at the US National Institutes of Health which has developed a standardized PROs methodology for early phase trials conducted in the Center for Cancer Research at the US National Cancer Institute.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 6","pages":"Pages 457-464"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy-related myelodysplastic syndromes and acute myeloid leukemia 与治疗相关的骨髓增生异常综合征和急性髓性白血病。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-12-01 DOI: 10.1053/j.seminhematol.2024.09.004

Sangeetha Venugopal , Amy E. DeZern

Progress always comes at a price: the field of oncology has seen unprecedented progress in treatment options recently for many solid and hematologic cancers. Unfortunately, these long-term survivors of prior cancer and cytotoxic therapy exposure are at higher risk of therapy-related myelodysplastic syndromes/acute myeloid leukemia (t-MDS/AML.) T-MDS/AML is a myeloid malignancy which occur after exposure to chemotherapy or radiation therapy for unrelated malignancy. T-MDS/AML is associated with adverse cytogenomic features and poor prognosis. While advances in the field of clonal hematopoiesis and germline variants has unraveled the molecular underpinnings of t-MDS/AML, we have miles to go in terms of t-MDS/AML directed therapy and improvement in outcomes. In this review, we discuss the epidemiology of t-MDS/AML, clinical and biological insights, evolution of t-MDS/AML and available treatment options.

进步总是要付出代价的：近来，肿瘤学领域在许多实体癌和血液肿瘤的治疗方案上取得了前所未有的进展。不幸的是，这些曾接受过癌症和细胞毒治疗的长期幸存者罹患与治疗相关的骨髓增生异常综合征/急性髓性白血病（t-MDS/AML）的风险较高。T-MDS/AML与不良细胞基因组特征和不良预后有关。虽然克隆造血和种系变异领域的研究进展已经揭示了t-MDS/AML的分子基础，但在t-MDS/AML的定向治疗和改善预后方面，我们还有很长的路要走。在这篇综述中，我们将讨论 t-MDS/AML 的流行病学、临床和生物学见解、t-MDS/AML 的演变以及现有的治疗方案。

引用次数: 0

CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies CARs 勇往直前：CAR T 细胞疗法在血液恶性肿瘤早期治疗过程中的发展。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.08.005

Omar Castaneda Puglianini , Julio C. Chavez

Chimeric antigen receptor T-cell (CAR-T) has revolutionized the treatment of hematologic malignancies. There are several approvals in lymphomas, leukemias and myeloma. Randomized clinical trials have shown that CAR-T cell therapy improves survival over standard of care in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), changing dramatically the current treatment paradigm. Current efforts are directed in improving outcomes in the frontline setting and confirmatory randomized trials are ongoing.

嵌合抗原受体 T 细胞（CAR-T）彻底改变了血液系统恶性肿瘤的治疗。目前已有数种淋巴瘤、白血病和骨髓瘤获得批准。随机临床试验表明，与标准疗法相比，CAR-T 细胞疗法提高了弥漫大 B 细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）的生存率，极大地改变了目前的治疗模式。目前的努力方向是改善一线治疗的疗效，确证性随机试验正在进行中。

引用次数: 0

CAR T-cell therapy comes of age: Introductory editorial for the special issue CAR T 细胞疗法时代的到来：特刊序言

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.10.003

Jennifer N. Brudno MD

引用次数: 0

The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL 多行不义必自毙--研究嵌合抗原受体T细胞疗法在B细胞ALL中的异基因造血干细胞移植的作用。

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology

Pub Date : 2024-10-01 DOI: 10.1053/j.seminhematol.2024.08.004

Michelle Choe MD , Corinne Summers MD

Treatment with CD19-targeted chimeric antigen receptor T cell therapy (CD19-CART) has improved salvage rates in children and adults with relapsed and/or refractory B-cell acute lymphoblastic leukemia (ALL). However, not all patients treated with CD19-CAR T cells achieve long-term remission. The role of allogeneic hematopoietic stem cell transplantation as consolidative therapy remains undefined. We aim to review the current literature published to date regarding prognostic markers indicating durable ALL response to CD19-CART and risk factors for relapse after CD19-CART to identify patient cohorts who may benefit from consolidative hematopoietic stem cell transplantation.

CD19 靶向嵌合抗原受体 T 细胞疗法（CD19-CART）提高了复发和/或难治性 B 细胞急性淋巴细胞白血病（ALL）儿童和成人患者的救治率。然而，并非所有接受 CD19-CAR T 细胞治疗的患者都能获得长期缓解。异基因造血干细胞移植作为巩固治疗的作用仍未确定。我们旨在回顾迄今为止发表的有关CD19-CART持久ALL反应预后标志物和CD19-CART后复发风险因素的文献，以确定哪些患者群体可从巩固性造血干细胞移植中获益。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Seminars in hematology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀